Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP
The hematologic oncologist at the Levine Cancer Institute discussed the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
This content originally appeared on our sister site,
OncLive spoke with Michael R. Grunwald, MD, FACP, clinical assistant professor of medicine, University of North Carolina, and hematologist/ oncologist, Levine Cancer Institute, Atrium Health, about the potential of tisagenlecleucel (Kymriah) in the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL).
Having a CAR T-cell therapy available for the treatment of patients with B-ALL has being exciting, Grunwald says. However, the agent is currently only FDA approved for use in patients up to age 25 years whose disease is refractory or in second or later relapse, Grunwald notes.
Further studies of tisagenlecleucel, as well as similar agents, will be important for older patients with B-ALL because more options are needed in this population, Grunwald continues. For younger patients, however, having this agent available has been significant, as it can get them back into remission. Sometimes patients who receive the agent can experience a very durable remission following relapse, Grunwald concludes.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Using Targeted Locus Amplification to Analyze Genetically Modified Cells
September 18th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025